peter kolchinsky age

Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. His primary responsibilities are to advise RA Capital on private investments, coordinate with portfolio companies regarding deal structures and terms, and counsel RA Ventures on new company formation. RA Capital makes no guarantees as to their accuracy or completeness. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. However he's a bit older than others, like Raquel Leviss, who is only 28 . Emory has a BS from Vassar College and an MD from the Harvard-MIT Health, Science, Technology Program at Harvard Medical School. She previously held roles as a Senior Business Analyst at Cambridge Associates and a Systems Analyst at Wellington Management Company. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. He holds a BA in Environmental Engineering from Dartmouth College (1998), an MA in International Finance and Energy Policy from John Hopkins University (2008), an MS in Materials Science from Columbia University (2012), and a Masters of Strategic Studies from the Army War College (2020). In this role he works closely with RAs Venture Team to evaluate various drug discovery platforms and initiate novel therapeutics programs. Michael conducts due diligence on biotechnology companies at RA Capital. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Sams primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds a BA in Neuroscience with a minor in Molecular and Cellular Biology from Colorado College. Emilies primary responsibility at RA Capital is to manage current and potential investor relationships. Natalie brings to RAVen more than six years of Administrative experience. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. Laura previously worked at WinterWyman where she served as a Senior Associate. During his time at Flagship, Tom also served as Co-Founder, Head of Translational Biology at a stealth ProtoCo. Support. Peter Kolchinsky Founder and CEO RA Capital Management. Gerald holds a PhD in Molecular and Cellular Biology from Harvard Medical School. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Prior to joining RAVen, Habib spent five years as President and CEO at Acceleron Pharma. Previously, Laura covered hematologic malignancies, cell therapies, retinal diseases, and orphan neurodevelopmental disorders. Sophie was a principal investigator in the Early Phase Trials Team at GSTT and has extensive experience in the delivery of early to late phase oncology trials. In this episode Peter speaks with Dr. Wayne Shreffler, Director of the Food Allergy Center at Massachusetts General Hospital & Division Chief of Pediatric Allergy and Immunology at MassGeneral Hospital for Children. Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. April 28, 2023 Updated: April 28, 2023 4:29 p.m. 8. Jeff Breay is a Head Trader at RA Capital Management. In this role he works closely with the RA Ventures team to evaluate and incubate early stage therapeutic programs. Prior to RA, Henry gained experience as an Investment Banking Analyst at SVB Leerink. David holds a PhD from Harvard University in Biophysics and a BS in Molecular Biology from Texas A&M University. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Jessica Sagers is Head of Engagement at RA Capital Management. Neil Buckley is an EIR at RA Capital. Dan Guglielmo is IT Operations Associate at RA Capital Management. Drinking, Drugs & Smoking Not present. Prior to Merck, he was a Partner with the Partners Innovation Fund, the corporate venture arm of Mass General Brigham hospital (formerly Partners HealthCare), where he invested in Seed/Series A therapeutics-focused companies. Brian previously worked at the Kraft Group LLC, where he led their system admin, network, and desktop engineering groups. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Harveys primary responsibility is to oversee all accounting related activities for the firm. Sophie is a Fellow of the Royal College of Physicians, London, UK. Founders GSAS Harvard Biotech Club Her contributions involve engagement with teams across RA Capital, including the processing of CDA's. He is a member of the Advisory Boards of the Applied Biotechnology Laboratory at the Francis Crick Institute, the Center for Surgery,Innovation & Bioengineering at the Massachusetts General Hospital/Harvard MedicalSchool; the Chemical& Biomolecular Engineering Department of the University of Illinois and the Biomedical Engineering Departmentof Rutgers University. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Emorys primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Soumya obtained his PhD in X-ray Crystallography and Biophysics from the Indian Institute of Science while working as visiting research scholar at Rockefeller University. James Schneider is the Deputy General Counsel at RA Capital Management. She worked previously in desktop publishing and as a freelance designer. Cristinas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Matthew Hammond is a Principal on the Investment Team at RA Capital Management. He is the co-founder and Chairman of the Board of Directors of Spero Therapeutics, and past President, CEO and member of the Board of Directors of Achillion Pharmaceuticals. Derek DiRocco is a Partner at RA Capital Management. Robert also led the Sequencing Operations and Technology Development groups at the Broad for over 12 years, implementing industrial process control methods, developing multiple generations of high-throughput DNA sequencing technologies, and establishing an agile learning culture in the organization. Prior to joining RA Capital and Arcuate Therapeutics, Tim was President and CEO of Proteon Therapeutics, a company focused on developing novel therapeutics to improve the lives of patients with kidney and vascular diseases. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Jon has a PhD in Biomedical Engineering from the University of Michigan, an MS in Mechanical Engineering from Boston University, and a BS in Physics from the University of Washington. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Jake works on both public and private investments and serves as a Board Director for Xenikos, B.V, Tyra Biosciences, AavantiBio, and DiCE Molecules. Peter Kolchinsky Phone Number, Address, Age, Contact Info, Public Prior to joining RAVen, Michael was the Executive Vice President and CMO at Point32Health, formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan. He conducted his postdoctoral research at Brigham and Womens Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Our website uses cookies to distinguish you from other users of our website. Sarah teaches a course at Harvard Law School on venture capital fund formation. James McArthur is an Advisor for RA Capital Management. The Great American Drug Deal | Peter Kolchinsky, PhD - NetGalley This is a re-publication of an op-ed that first appeared in the Wall Street Journal on September 30, 2018 and is now included in The Biotech Social Contract series of . Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Peter Kolchinsky is a founder and managing partner at RA Capital Management and author of "The Great American Drug Deal" (Evelexa Press, 2020). His responsibilities include managing the portfolios public equity positions, monitoring market, sector, and individual equity dynamics, and maintaining relationships with broker/dealer counterparties. He holds a BS in Computer Science from Northeastern University. Kolchinsky's mom knew her son was gifted - Boston Business Journal What is Peter Kolchinsky Net Worth? Not so long ago, his mother and father were not rich. Most recently, Brian served as Analyst, Biotech/Pharma/Specialty Pharma at Tamarack Capital Management. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. Priscilla Lee is an Associate within the TechAtlas division of RA Capital Management. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Ed Monaghan is an EIR at RA Capital. Brackett has a BS in Biology with a minor in Spanish from Davidson College. Mario is responsible for partnering with several of our portfolio companies as Board Member or Technical Advisor. Matt Beverly is a Senior Software Engineer at RA Capital Management. Jon Lundt is a Senior Associate within the TechAtlas division of RA Capital Management. Prior to that, Tom held an Operations Supervisor role at Bracebridge Capital, LLC and operations positions at Harvard Management Company and State Street Corporation. Americas +1 212 318 2000. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. Shannon is a Receptionist and Facilities Administrator at RA Capital Management. Alex Martinez-Forte is an Analyst, Strategic Finance at RA Capital Management. No Patient Left Behind | Steering committee | Peter Kolchinsky After his stay at IncTank Ventures, he joined Schrdingers Drug Discovery Application Group and through various roles ascended to a Research Leader within the organization. Tyler Kowalski is an InteractiveDesigner at RA Capital Management. She received a BA from Princeton University and an MBA from Harvard Business School. Peter Kolchinsky Net Worth | Age, Height, Weight, Dating And More Cony received a BSc in Applied Biology from the University of London and an MBA from The Open University, Milton Keynes UK. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. Shan Shan Wang is an Associate Director within the TechAtlas division at RA Capital Management. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Kyle also recently retired as a Colonel in the US Army Reserve after 24 years of service. Henry Stusnick is an Associate at RA Capital Management. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Prior to joining RAVen, Joel was co-founder, President and Chief Scientific Officer at Jnana Therapeutics, a platform company focused on unlocking hard-to-drug targets. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Joel is currently a Venture Partner at RA Ventures focusing on new company creation. Daphne Zohar is the founder and CEO of PureTech. Benjamins primary responsibilities at RA Capital are to coordinate various projects across the Venture Team and oversee their initiation, planning, and execution. Emily Minkow is a Venture Partner at RA Ventures. Megan has a BS in Microbiology & Cell Science from University of Florida. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Asthas previous experience includes Research Assistant roles at Clark University and Corbus Pharma. Prior to Schrdinger, Cony was President Chief Business Officer at Proteros responsible for all commercial activities. Anurag works on both public and private investments with a focus on Healthcare, Technology, and Services. Jess'sprimary responsibility is to direct a concerted effort to analyze, design, and shape internal and external narratives. Matts primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Zach holds a BS in Molecular Biophysics and Biochemistry from Yale University, and a PhD in Neurobiology and Behavior from the University of Washington. Tylers primary responsibility at RA Capital isdesigning and maintaining the RA Capital website and assisting in the creation and design of interactive platforms at RA Capital and it's portfolio companies founded through the firm's incubator, RA Ventures. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. Her primary responsibilities are to assist with all finance operations related to the Firm. In this role, he works closely with the RA Venture team to evaluate and incubate early-stage therapeutic programs. He holds a BS in Finance from Providence College. Josh was previously co-lead of SV Health Investors US Biotech practice where he was responsible for SVs US venture creation activities, including its incubator, Brahma Discovery. His graduate research investigated the role of fimbria in Bordetella adherence and virulence. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Laura works on new company creation and early-stage investments, and serves as a Board Director for Be Biopharma, Expansion Therapeutics, Hemab, and Aliada Therapeutics. Derek works on both public and private investments and serves as a Board Director for 89Bio, Achilles Therapeutics, iTeos Therapeutics, Connect Bio, CANbridge, andWerewolf Therapeutics. Currently, Dr. Kolchinsky occupies the position of Chairman & Chief Executive Officer of Research Alliance Corp. II (which he founded in 2020) and Managing Partner at RA Capital Management LP (which he founded in 2004), Managing Partner at RA Capital Management LP (Private Equity) (which he founded) (a subsidiary of RA Capital Management LP). He holds Microsoft 365 and Microsoft certifications as Messaging Administrator Associate, Teams Administrator Associate, Teamwork Administrator Associate, and Azure Administrator Associate. TJ is a Senior Fund Accountant at RA Capital Management. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. in Biochemistry and a Ph.D. in Pharmaceutical Sciences from the University of Toronto, Canada. Christina is a Senior Science Writer at RA Capital Management. Let's Throw a Patent-Burning Party | by Peter Kolchinsky - Medium Megans primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. His most recent role at Biogen was as Senior Vice President, U.S. Commercial, where he was the general manager of the MS, hemophilia, and SMA franchises. Laura holds a BA in Biology and Psychology from Harvard University, and a PhD in Neuroscience from MIT. He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. He was Chief Medical Officer of Ra Pharmaceuticals from 2016 until it was acquired by UCB in 2020. Her graduate research investigated novel epigenetic regulators in glioblastoma. Alyssas primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Sarah is the only lawyer to have received the NVCAs Outstanding Service Award, for her leadership role in conceiving of and spearheading the NVCA Model Legal Documents. Peter Pan & Wendy Movie Review | Common Sense Media Jaime is an Executive Assistant at RA Ventures (RAVen). By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. She holds a BBA in Marketing from Loyola University Maryland. Milind attended the residential Executive Program at The Wharton School of Management. Prior to MassTech, Natalie held varying Administrative roles at Northeastern University, Framingham Public Schools, and Bright Horizons Family Solutions. Anas previous experience includes Research Assistant positions at Massachusetts Eye and Ear Hospital, the Lupus Clinic/Renal Department at the BU Medical Center, and Harvard University Department of Molecular and Cellular Biology. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Massachusetts General Hospital. Biohaven Closes Second Tranche Of Private Placement And Appoints Two He had to juggle the demands of raising a family while also trying to pay for his children's education. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. She received a B.Sc. Brigid was responsible for starting the venture fund and led investments in multiple sectors, including advanced analytics platforms, biomining and bioremediation, novel chemical leaching, long-duration energy storage, traceability of products, carbon removal, and green steel. Peter Kolchinsky Benjamin Hicks is a Venture Operations Associate at RA Capital Management. Prior to these companies, James held senior research leadership roles in the gene and stem cell therapy companies Cell Genesys, Phylogix, and Somatix Therapy. Danielle Feldman is the Director of Corporate Development at Aliada Therapeutics. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. He worked previously as a Patient Coordinator at Massachusetts General Hospital. They will discuss the origins and history . Her primary responsibilities are to coordinate calendars, events, travel and meetings for the Venture Partners and Entrepreneurs-In-Residence within RAVen. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Timothy Noyes is an Advisor for RA Capital Management. Joel received his doctorate in Organic Chemistry from Columbia University and his bachelors in Chemistry from the University of Pennsylvania. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). Nadim Shohdy is an EIR at RA Capital. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Rez holds a BSc in biochemistry and PhD in cell biology from Newcastle University, UK. Meredith is a Senior Research Assistant at RA Capital Management. Prior to GHP, Lorena served as an Assurance Senior at EY. Lorena's primary responsibility is to oversee all accounting related activities for the firm. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Prior to this, he was a Postdoctoral Fellow at NYU Medical School in the laboratory of Dr. Danny Reinberg, exploring the functional downstream consequences of changes to the histone posttranslational modification landscape on processes that require access to DNA, including the regulation of gene expression. Kathryn Meng is an Investment Director within the Planetary Health division of RA Capital. So it's not patents holding back production. Vanderpump Rules: How Old Is Peter Madrigal? - Screen Rant He is active in both public and private investments In biotechnology areas as diverse as drugs, medical devices, diagnostics, and life science tools. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Robert Nicol is a Venture Partner at RA Ventures (RAVen), focusing on company creation. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Barrie's 1911 novel. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Peter Kolchinsky's Post - LinkedIn Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. By Matt Grobar. Cosmass academic research has been published in journals such as Cell, Science, and Nature. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. But there are only so many vaccine experts. Ramin is an experienced clinical trialist and previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences. Sri Mahendra is a Senior Software Engineer at RA Capital Management. Lucas previously held Law Clerk positions at The Community Builders, Inc. and at Nixon Peabody LLP. in Biomedical Anthropology from the University of Pennsylvania. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Garrett has over 20 years of experience in cell and gene therapy, including over 12 years in roles of increasing responsibility in biotech companies, including with Bluebird Bio, Audentes Therapeutics, and Ambys Medicines, and he was most recently the VP of Gene Therapy at Voyager Therapeutics. She has published over fifty papers in peer reviewed journals. Dan Marks is a Principal on the Venture Team at RA Capital Management. Laura has a BS in Chemistry from Yale University and a PhD in Chemical Biology from Harvard University. Many of the assets he contributed to within HNDC have been out-licensed to various Cambridge and Boston-based startups and biotech firms for further development.
Italian Industrial Workers In Argentina Pull Factors, Articles P